Impaired interferon signaling is a common immune defect in human cancer

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2009-06-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.0901329106PMID 19451644PMCID PMC2690021
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus.

  2008cited by this paper
• Down-Regulation of the Interferon Signaling Pathway in T Lymphocytes from Patients with Metastatic Melanoma

  2007cited by this paper
• Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race

  2006cited by this paper
• Cutting Edge: Enhancement of Antibody Responses Through Direct Stimulation of B and T Cells by Type I IFN1

  2006cited by this paper
• Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.

  2006cited by this paper
• Cutting Edge: The Direct Action of Type I IFN on CD4 T Cells Is Critical for Sustaining Clonal Expansion in Response to a Viral but Not a Bacterial Infection1

  2006cited by this paper
• Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

  2006cited by this paper
• Dynamic regulation of IFN-gamma signaling in antigen-specific CD8+ T cells responding to infection.

  2005cited by this paper
• Dynamic Regulation of IFN-γ Signaling in Antigen-Specific CD8+ T Cells Responding to Infection1

  2005cited by this paper
• Cutting Edge: Type I IFNs Provide a Third Signal to CD8 T Cells to Stimulate Clonal Expansion and Differentiation1

  2005cited by this paper
• Interferon-α activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-α secretion by immature human natural killer cells

  2005cited by this paper
• TGF-β1 Inhibits T-bet Induction by IFN-γ in Murine CD4+ T Cells through the Protein Tyrosine Phosphatase Src Homology Region 2 Domain-Containing Phosphatase-11

  2005cited by this paper
• The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon‐α treatment

  2005cited by this paper
• TGF-beta1 inhibits T-bet induction by IFN-gamma in murine CD4+ T cells through the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1.

  2005cited by this paper
• Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck

  2004cited by this paper
• A Dual Role of IFN-α in the Balance between Proliferation and Death of Human CD4+ T Lymphocytes during Primary Response1

  2004cited by this paper
• Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells1

  2004cited by this paper
• Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

  2004cited by this paper
• Granulocyte‐macrophage–colony‐stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

  2003cited by this paper
• IGF-1 down-regulates IFN-gamma R2 chain surface expression and desensitizes IFN-gamma/STAT-1 signaling in human T lymphocytes.

  2003cited by this paper
• IGF-1 down-regulates IFN-γR2 chain surface expression and desensitizes IFN-γ/STAT-1 signaling in human T lymphocytes

  2003cited by this paper
• On Distribution-Free Tests for the Multivariate Two-Sample Location-Scale Model

  2002cited by this paper
• Interferon γ Is Required for Activation-induced Death of T Lymphocytes

  2002cited by this paper
• Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

  2002cited by this paper
• Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.

  2002cited by this paper
• Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma.

  2001cited by this paper
• Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma.

  2000cited by this paper
• Interleukin-10 Inhibits Expression of Both Interferon – and Interferon γ– Induced Genes by Suppressing Tyrosine Phosphorylation of STAT1

  1999cited by this paper
• An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions

  1999cited by this paper
• Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1.

  1999cited by this paper
• Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

  1999cited by this paper
• Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression.

  1999cited by this paper
• Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.

  1998cited by this paper
• Inhibition of Stat1-mediated gene activation by PIAS1.

  1998cited by this paper
• Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.

  1998cited by this paper
• A family of cytokine-inducible inhibitors of signalling

  1997cited by this paper
• Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma.

  1996cited by this paper
• Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells.

  1995cited by this paper
• Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

  1994cited by this paper
• Interferon—A Major Regulator of Natural Killer Cell-Mediated Cytotoxicity

  1993cited by this paper
• IL-4 attenuates the transcriptional activation of both IFN-alpha and IFN-gamma-induced cellular gene expression in monocytes and monocytic cell lines.

  1993cited by this paper

• Molecular, Functional, and Ecological Characterization of Antarctic Penguin Orthoavulaviruses (AVV17-19).

  2026cites this paper
• Peritumoral macrophages recruit eosinophils to promote antitumor immune responses in breast cancer.

  2025cites this paper
• Oncolytic virus and immunogenic cell death in cancer therapy

  2025cites this paper
• Proteomic analysis of exosomes from lymphatic affluents reveals their implications in developing premetastatic niche in melanoma

  2025cites this paper
• Pre-Encoded IFN-I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors.

  2025cites this paper
• Ligand Discrimination in Immune Cells: Signal Processing Insights into Immune Dysfunction in ER+ Breast Cancer

  2025cites this paper
• Proteomic Analysis of Small Extracellular Vesicles From Lymphatic Affluents in Developing Premetastatic Niche in Melanoma

  2025cites this paper
• Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells

  2025cites this paper
• The recurrence or metastasis related gene predicts the prognosis of extremity and trunk soft tissue sarcoma

  2025cites this paper
• Ferroptosis triggers anti-tumor immunity via promoting chaperone-mediated autophagic degradation of SHP2

  2025cites this paper
• Ligand discrimination in immune cells: Signal processing insights into immune dysfunction in ER+ breast cancer

  2025cites this paper
• The Small GTPase Ran Increases Sensitivity of Ovarian Cancer Cells to Oncolytic Vesicular Stomatitis Virus

  2024cites this paper
• Metabolic adaptations determine whether natural killer cells fail or thrive within the tumor microenvironment

  2024cites this paper
• Disruption of polyunsaturated fatty acid biosynthesis drives STING-dependent acute myeloid leukemia cell maturation and death

  2024cites this paper
• Elevated extracellular vesicular Nm23-H1 subdues the pro-migratory potential of breast cancer cell-derived extracellular vesicles.

  2024cites this paper
• Systems profiling reveals recurrently dysregulated cytokine signaling responses in ER+ breast cancer patients’ blood

  2024cites this paper
• A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor.

  2024cites this paper
• Grainyhead-like-2, an epithelial master programmer, promotes interferon induction and suppresses breast cancer recurrence.

  2024cites this paper
• Bridging the gap between tumor and disease: Innovating cancer and glioma models

  2024cites this paper
• Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities

  2024cites this paper
• Virus nanotechnology for intratumoural immunotherapy

  2024cites this paper
• Dual‐Epigenetically Relieving the MYC‐Correlated Immunosuppression via an Advanced Nano‐Radiosensitizer Potentiates Cancer Immuno‐Radiotherapy

  2024cites this paper
• PKR induces TGF-β and limits oncolytic immune therapy

  2023cites this paper
• Natural Oncolysis of Enterovirus 71 in Antitumor Therapy of Colorectal Cancer

  2023cites this paper
• Optimal delivery of RNA interference by viral vectors for cancer therapy.

  2023cites this paper
• SARS-CoV-2 Vaccination and the Multi-Hit Hypothesis of Oncogenesis

  2023cites this paper
• Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer

  2023cites this paper
• Systems profiling reveals recurrently dysregulated cytokine signaling responses in ER+ breast cancer patients’ blood

  2023cites this paper
• Identification of genomic biomarkers and their pathway crosstalks for deciphering mechanistic links in glioblastoma

  2023cites this paper
• In Vitro Analysis of Anticancer Potential of Green Okra (Abelmoschus esculentus L.) Polysaccharide Extracts in HeLa Cervical Cancer Cell Line

  2023cites this paper
• Phosphoflow cytometry to assess cytokine signaling pathways in peripheral immune cells: potential for inferring immune cell function and treatment response in patients with solid tumors

  2023cites this paper
• Type I interferons and Mycobacterium tuberculosis whole cell lysate induce distinct transcriptional responses in M. tuberculosis infection.

  2023cites this paper
• Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy

  2023cites this paper
• La-related protein 4 is enriched in vaccinia virus factories and is required for efficient viral replication in primary human fibroblasts

  2023cites this paper
• La-related protein 4 is enriched in vaccinia virus factories and is required for efficient viral replication in primary human fibroblasts

  2023cites this paper
• Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

  2022cites this paper
• Paclitaxel and cancer treatment: Non-mitotic mechanisms of paclitaxel action in cancer therapy

  2022cites this paper
• The Transcription Factor IRF9 Promotes Colorectal Cancer via Modulating the IL-6/STAT3 Signaling Axis

  2022cites this paper
• Senescence-induced endothelial phenotypes underpin immune-mediated senescence surveillance

  2022cites this paper
• Pathological Correlation of Lymphocyte Cytosolic Protein 1 in Gastric Cancer and its Effect on Tumor Immune Infiltration

  2022cites this paper
• The gamble between oncolytic virus therapy and IFN

  2022cites this paper
• Immune Cell-Camouflaged Surface-Engineered Nanotherapeutics for Cancer Management.

  2022cites this paper
• Analysis of the role of m6A and lncRNAs in prognosis and immunotherapy of hepatocellular carcinoma

  2022cites this paper
• Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy

  2022cites this paper
• The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance

  2022cites this paper
• A host non-coding RNA, nc886, plays a pro-viral role by promoting virus trafficking to the nucleus

  2022cites this paper
• In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis

  2022cites this paper
• Characterization of osteosarcoma subtypes mediated by macrophage-related genes and creation and validation of a risk score system to quantitatively assess the prognosis of osteosarcoma and reflect the tumor microenvironment

  2022cites this paper
• Obesity Influences the Expression of Key Immunomodulators in Normal Human Breast Tissue, Basal-like Breast Cancer Patients, and Cell Lines

  2022cites this paper
• Identification of Transferrin Receptor 1 (TfR1) Overexpressed in Lung Cancer Cells, and Internalization of Magnetic Au-CoFe2O4 Core-Shell Nanoparticles Functionalized with Its Ligand in a Cellular Model of Small Cell Lung Cancer (SCLC)

  2022cites this paper
• The downregulation of type I IFN signaling in G-MDSCs under tumor conditions promotes their development towards an immunosuppressive phenotype

  2022cites this paper
• Interferon epsilon and preterm birth subtypes; a new piece of the type I interferon puzzle during pregnancy?

  2022cites this paper
• The expanding roles of neuronal nitric oxide synthase (NOS1)

  2022cites this paper
• Using viral vectors to deliver local immunotherapy to glioblastoma.

  2021cites this paper
• SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms

  2021cites this paper
• Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacitidine.

  2021cites this paper
• Modeling Innate Antiviral Immunity in Physiological Context.

  2021cites this paper
• Type I Interferons as Joint Regulators of Tumor Growth and Obesity

  2021cites this paper
• Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies

  2021cites this paper
• Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer

  2021cites this paper
• Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy

  2021cites this paper
• Detecting spatially co-expressed gene clusters with functional coherence by graph-regularized convolutional neural network

  2021cites this paper
• Type I Interferon Induction in Cutaneous DNA Damage Syndromes

  2021cites this paper
• Diversity in responses to oncolytic Lassa-vesicular stomatitis virus in patient-derived glioblastoma cells

  2021cites this paper
• Double-edged effects of interferons on the regulation of cancer-immunity cycle

  2021influential citation
• The Multifaceted Role of Macrophages in Oncolytic Virotherapy

  2021cites this paper
• Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data

  2021cites this paper
• Chemotherapy-induced cytokines and prognostic gene signatures vary across breast and colorectal cancer.

  2021cites this paper
• T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy

  2021cites this paper
• The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery

  2021influential citation
• Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges

  2021cites this paper
• Structure of the poxvirus decapping enzyme D9 reveals its mechanism of cap recognition and catalysis

  2021cites this paper
• Systemic Correlates of the Tumor Microenvironment.

  2020cites this paper
• Interferon α in cancer immunoediting: From elimination to escape

  2020cites this paper
• CARs: Beyond T Cells and T Cell-Derived Signaling Domains

  2020cites this paper
• COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

  2020cites this paper
• Identification of a Novel Signature and Construction of a Nomogram Predicting Overall Survival in Clear Cell Renal Cell Carcinoma

  2020cites this paper
• Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy

  2020cites this paper
• Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.

  2020cites this paper
• Bioinformatic Analysis of Correlation between Immune Infiltration and COVID-19 in Cancer Patients

  2020influential citation
• In vivo characterization of a pseudotyped vesicular stomatitis virus for the treatment of Hepatocellular carcinoma

  2020cites this paper
• Triggering interferon signaling in T cells with avadomide sensitizes chronic lymphocytic leukemia to anti-PD-L1/PD-1 immunotherapy

  2020cites this paper
• Deletion of Glutathione S-Transferase Omega 1 Activates Type I Interferon Genes and Downregulates Tissue Factor

  2020cites this paper
• CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner

  2020cites this paper
• MAP3K7 and CHD1 Are Novel Mediators of Resistance to Oncolytic Vesicular Stomatitis Virus in Prostate Cancer Cells

  2020cites this paper
• Triggering interferon signaling in T cells with avadomide sensitizes chronic lymphocytic leukemia to anti-PD-L1/PD-1 immunotherapy

  2020cites this paper
• Status of Immune Oncology: Challenges and Opportunities.

  2020cites this paper
• Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response

  2019cites this paper
• Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes

  2019cites this paper
• Type I interferons and dendritic cells in cancer immunotherapy.

  2019cites this paper
• NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2

  2019cites this paper
• PAC-5 Gene Expression Signature for Predicting Prognosis of Patients with Pancreatic Adenocarcinoma

  2019cites this paper
• Ribosome biogenesis restricts innate immune responses to virus infection and DNA

  2019cites this paper
• Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints.

  2019cites this paper
• M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells

  2019cites this paper
• Human IFIT proteins inhibit lytic replication of KSHV: A new feed-forward loop in the innate immune system

  2019cites this paper
• Development and Characterization of a Fixed Repertoire of Blood Transcriptome Modules Based on Co-expression Patterns Across Immunological States

  2019cites this paper
• TGFβ blocks IFNα/β release and tumor rejection in spontaneous mammary tumors

  2019cites this paper
• The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer

  2019cites this paper
• Virus-Based Immunotherapy of Glioblastoma

  2019cites this paper